Assessment of TLR immunomodulators in oncology and HIV

Challenge:  A European publicly-listed biotech was facing a Phase III milestone for its lead immunomodulator and had a next generation technology in IND-enabling studies. The company was operating in...
Learn More

Deal benchmarks & term sheet appraisal for an early-stage license deal

Project Challenge: An early stage investor was in the midst of setting up a NewCo for the research and development of novel treatments using a fairly under-researched area of cell biology. However, a...
Learn More

Investor due diligence of a development-stage microbiome company

Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....
Learn More

Investor Due Diligence: Pharma Business Development Case Studies

Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...
Learn More

Pharmaceutical Licensing: Negotiation Support

Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...
Learn More

Due diligence: biologic technologies & phase III probability of success of CNS asset

Case Study 1, Challenge: A mid-size pharmaceutical company seeking opportunities to diversify within its core therapeutic area by partnering in products based on biologic technologies retained...
Learn More

Due diligence of a plasma protein manufacturer for a PE investor

Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in the...
Learn More

Developing an independent market report for a cannabinoid company seeking a dual-listing

Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...
Learn More

Due diligence on a new medical imaging technology

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More

Valuation of a cancer therapy for licensing deal

Challenge: A biotech company developing small molecule drugs for oncology was in the process of licensing negotiations with a pharma company for its lead asset. The asset, set to enter the clinic in...
Learn More

Due diligence on a novel T cell therapy and discovery platform

Challenge: A VC investor wished to make an investment in a California-based preclinical biotechnology company with a discovery platform and novel T cell therapies for cancer and other diseases....
Learn More

Acquisition & licensing landscape for technologies in fertility & women’s health

Challenge: In order to better review potential acquisition and licensing opportunities, a pharma company asked Alacrita to landscape the companies, medical devices, digital technologies, research...
Learn More
Content not found